{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T04:55:12Z","timestamp":1784782512792,"version":"3.55.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ferring Arzneimittel GmbH Kiel, Germany","award":["000150"],"award-info":[{"award-number":["000150"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Aims<\/jats:title>\n                  <jats:p>The course of Crohn\u2019s disease (CD) is highly variable. The Prospektive Evaluation eines Score zur Vorhersage eines milden Verlaufsbei neu diagnostizierten Morbus Crohn-Patienten in gastroenterologischen Fachpraxen (PROGNOS) study aimed to determine the frequency of a mild disease course and validate a proposed prediction score.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The PROGNOS study is a prospective study of CD patients who were newly diagnosed and, except for 1 course of 5-aminosalicylic acid or steroids for \u226410 days, therapy-na\u00efve. Among other predefined inclusion criteria, the initial diagnosis had to be made \u22646 weeks before enrollment. All inception cohort patients were diagnosed and screened consecutively in participating gastroenterology practices in Germany specialized in inflammatory bowel disease. All screened CD patients were scored and, if possible, included in the study for up to 5 years (NCT02193048).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 201 CD patients were included in the study (43.3% male; mean age 33 years, mean follow-up 38 months). Altogether, 29.5% of the patients had a mild course at 36 months. Among those with a score \u22642, therapy escalation at 36 months was necessary for only 24.2%, whereas in the group with a score &amp;gt;2, therapy escalation was necessary for 70.2% of patients. In the Kaplan-Meier curve showing time to therapy escalation in the 2 groups, there was a pronounced and statistically significant divergence of the curves starting at 3 months and extending to 48 months (P\u2005&amp;lt;\u2005.001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In this prospective study, about 30% of incident CD patients had a mild disease course. Our suggested PreMiCC (prediction score for a mild course of Crohn\u2019s disease) successfully predicted this.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ibd\/izae086","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T17:49:58Z","timestamp":1713808198000},"page":"677-685","source":"Crossref","is-referenced-by-count":3,"title":["Prospective Evaluation of the Prediction Score for a Mild Course of Crohn\u2019s Disease (PreMiCC) in Newly Diagnosed Patients With Crohn\u2019s Disease: The PROGNOS Study"],"prefix":"10.1093","volume":"31","author":[{"given":"Wolfgang","family":"Kruis","sequence":"first","affiliation":[{"name":"Internal Medicine, Protestant Hospital , Cologne ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2016-6991","authenticated-orcid":false,"given":"Bernd","family":"Bokemeyer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Interdisciplinary Crohn Colitis Centre , Minden ,","place":["Germany"]},{"name":"Clinic of General Internal Medicine I, University Hospital Schleswig-Holstein , Campus Kiel, Kiel ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Jessen","sequence":"additional","affiliation":[{"name":"Gastroenterology Practice , Kiel-Altenholz ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hoesl","sequence":"additional","affiliation":[{"name":"Gastroenterology Practice Clinic , Nuremberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mro\u00df","sequence":"additional","affiliation":[{"name":"Gastroenterology Practice , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Morgenstern","sequence":"additional","affiliation":[{"name":"Internal Medicine, Protestant Hospital , Cologne ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitta","family":"Reimers","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine , Ferring Arzneimittel GmbH, Kiel ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nike","family":"M\u00fcller-Grage","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine , Ferring Arzneimittel GmbH, Kiel ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludger","family":"Leifeld","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine , St. Bernward Hospital, Hildesheim ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,22]]},"reference":[{"issue":"9613","key":"2025030423102502000_CIT0001","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","article-title":"Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn\u2019s disease: an open randomised trial","volume":"371","author":"D\u2019Haens","year":"2008","journal-title":"Lancet."},{"issue":"8","key":"2025030423102502000_CIT0002","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/apt.13363","article-title":"Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn\u2019s disease","volume":"42","author":"Safroneeva","year":"2015","journal-title":"Aliment Pharmacol Ther."},{"issue":"1","key":"2025030423102502000_CIT0003","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J Crohns Colitis."},{"issue":"2","key":"2025030423102502000_CIT0004","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/ajg.2009.579","article-title":"The natural history of adult Crohn\u2019s disease in population-based cohorts","volume":"105","author":"Peyrin-Biroulet","year":"2011","journal-title":"Am J Gastroenterol."},{"issue":"6","key":"2025030423102502000_CIT0005","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.cgh.2019.11.034","article-title":"Identifying patients with inflammatory bowel diseases at high vs low risk of complications","volume":"18","author":"Siegel","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"6","key":"2025030423102502000_CIT0006","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1002\/ibd.21506","article-title":"Development of the Crohn\u2019s disease digestive damage score, the Lemann score","volume":"17","author":"Pariente","year":"2011","journal-title":"Inflamm Bowel Dis."},{"issue":"24","key":"2025030423102502000_CIT0007","doi-asserted-by":"publisher","first-page":"3866","DOI":"10.3748\/wjg.v19.i24.3866","article-title":"Clinical prognostic factors for disabling Crohn\u2019s disease: a systematic review and meta-analysis","volume":"19","author":"Dias","year":"2013","journal-title":"World J Gastroenterol."},{"issue":"5","key":"2025030423102502000_CIT0008","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1080\/00365520601076124","article-title":"Clinical course in Crohn\u2019s disease: results of a five-year population-based follow-up study (the IBSEN study)","volume":"42","author":"Henriksen","year":"2007","journal-title":"Scand J Gastroenterol."},{"issue":"30","key":"2025030423102502000_CIT0009","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.3748\/wjg.v25.i30.4235","article-title":"Natural history of children with mild Crohn\u2019s disease","volume":"25","author":"Sharma","year":"2019","journal-title":"World J Gastroenterol."},{"issue":"12","key":"2025030423102502000_CIT0010","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/j.cgh.2007.09.002","article-title":"Clinical course in Crohn\u2019s disease: results of a Norwegian population-based ten-year follow-up study","volume":"5","author":"Solberg","year":"2007","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"7","key":"2025030423102502000_CIT0011","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.crohns.2012.10.012","article-title":"Predictive factors for an uncomplicated long-term course of Crohn\u2019s disease: a retrospective analysis","volume":"7","author":"Kruis","year":"2013","journal-title":"J Crohns Colitis."},{"key":"2025030423102502000_CIT0012","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.cgh.2020.06.069","article-title":"Early indolent course of Crohn\u2019s disease in newly diagnosed patients is not rare and possibly predictable","volume":"19","author":"Yanai","year":"2021","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025030423102502000_CIT0013","article-title":"Update on non-progressive CD project","volume-title":"ECCO News","author":"Pierik","year":"2017"},{"issue":"4","key":"2025030423102502000_CIT0014","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/ajg.2011.19","article-title":"The prognostic power of the NOD2 genotype for complicated Crohn\u2019s disease: a meta-analysis","volume":"106","author":"Adler","year":"2011","journal-title":"Am J Gastroenterol."},{"issue":"12","key":"2025030423102502000_CIT0015","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/apt.13641","article-title":"Serologic microbial associated markers can predict Crohn\u2019s disease behaviour years before disease diagnosis","volume":"43","author":"Choung","year":"2016","journal-title":"Aliment Pharmacol Ther."},{"issue":"10080","key":"2025030423102502000_CIT0016","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/S0140-6736(17)30317-3","article-title":"Prediction of complicated disease course for children newly diagnosed with Crohn\u2019s disease: a multicentre inception cohort study","volume":"389","author":"Kugathasan","year":"2017","journal-title":"Lancet."},{"issue":"2","key":"2025030423102502000_CIT0017","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/ng.3755","article-title":"Genome-wide association study identifies distinct genetic contributions to prognosis and susceptibility in Crohn\u2019s disease","volume":"49","author":"Lee","year":"2017","journal-title":"Nat Genet."},{"issue":"2","key":"2025030423102502000_CIT0018","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/apt.13460","article-title":"A validated web-based tool to display individualised Crohn\u2019s disease predicted outcomes based on clinical, serologic and genetic variables","volume":"43","author":"Siegel","year":"2016","journal-title":"Aliment Pharmacol Ther."},{"issue":"1","key":"2025030423102502000_CIT0019","doi-asserted-by":"publisher","first-page":"e00188-17","DOI":"10.1128\/mSystems.00188-17","article-title":"Gut microbiota offers universal biomarkers across ethnicity in inflammatory bowel disease diagnosis and infliximab response prediction","volume":"3","author":"Zhou","year":"2018","journal-title":"mSystems"},{"issue":"8","key":"2025030423102502000_CIT0020","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1136\/gutjnl-2019-318343","article-title":"A blood-based prognostic biomarker in IBD","volume":"68","author":"Biasci","year":"2019","journal-title":"Gut."},{"issue":"8","key":"2025030423102502000_CIT0021","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1055\/s-2006-951071","article-title":"Morbus Crohn Patienten in der Gastroenterologischen Fachpraxis \u2013 gibt es den leichten auf 5-ASA ansprechenden Verlauf","volume":"44","author":"Bokemeyer","year":"2006","journal-title":"Z Gastroenterol."},{"issue":"3","key":"2025030423102502000_CIT0022","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1055\/a-1713-3941","article-title":"Aktualisierte S3-Leitlinie \u201eDiagnostik und Therapie des Morbus Crohnder\u201d Deutschen Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) \u2013 August 2021 \u2013 AWMF\u2013Registernummer: 021-004","volume":"60","author":"Sturm","year":"2022","journal-title":"Z Gastroenterol."},{"issue":"8","key":"2025030423102502000_CIT0023","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1177\/2050640620945949","article-title":"The use of 5-aminosalicylate for patients with Crohn\u2019s disease in a prospective European inception cohort with 5 years follow-up - an Epi-IBD study","volume":"8","author":"Burisch","year":"2020","journal-title":"United European Gastroenterol J"},{"issue":"3","key":"2025030423102502000_CIT0024","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1093\/ecco-jcc\/jjaa173","article-title":"Disease activity patterns of Crohn\u2019s disease in the first ten years after diagnosis in the population-based IBD South Limburg cohort","volume":"15","author":"Wintjens","year":"2021","journal-title":"J Crohns Colitis."},{"issue":"9","key":"2025030423102502000_CIT0025","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1111\/apt.17419","article-title":"5-aminosalicylate maintenance is not superior to no maintenance in patients with newly diagnosed Crohn\u2019s disease-A nationwide cohort study","volume":"57","author":"Atia","year":"2023","journal-title":"Aliment Pharmacol Ther."},{"issue":"5","key":"2025030423102502000_CIT0026","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.crohns.2010.06.002","article-title":"5-aminosalicyclic acid dependency in Crohn\u2019s disease: a Danish Colitis Database study","volume":"4","author":"Duricova","year":"2010","journal-title":"J Crohns Colitis."},{"issue":"12","key":"2025030423102502000_CIT0027","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1136\/gutjnl-2017-314519","article-title":"Early intervention in Crohn\u2019s disease: towards disease modification trials","volume":"66","author":"Danese","year":"2017","journal-title":"Gut."},{"issue":"4","key":"2025030423102502000_CIT0028","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/ajg.2018.27","article-title":"ACG clinical guideline: management of Crohn\u2019s disease in adults","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am J Gastroenterol."},{"issue":"5","key":"2025030423102502000_CIT0029","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology."},{"issue":"2","key":"2025030423102502000_CIT0030","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.crohns.2010.12.006","article-title":"The clinical implication of drug dependency in children and adults with inflammatory bowel disease: a review","volume":"5","author":"Duricova","year":"2011","journal-title":"J Crohns Colitis."},{"issue":"2","key":"2025030423102502000_CIT0031","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1053\/j.gastro.2010.11.004","article-title":"Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn\u2019s disease","volume":"140","author":"Tromm","year":"2011","journal-title":"Gastroenterology."},{"issue":"6","key":"2025030423102502000_CIT0032","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s11377-007-0113-6","article-title":"CED-Behandlung in Deutschland: Betrachtungen zur sinnvollen Vernetzung","volume":"2","author":"Bokemeyer","year":"2007","journal-title":"Gastroenterologe"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/3\/677\/57303114\/izae086.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/3\/677\/57303114\/izae086.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T23:11:23Z","timestamp":1741129883000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/31\/3\/677\/7655980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,22]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,4,22]]},"published-print":{"date-parts":[[2025,3,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izae086","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,4,22]]}}}